Tag: technology
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-
Why AstraZeneca Says Drug Development Must Move at “Chinese Speed”
AstraZeneca believes the next pharmaceutical race will be defined not only by scientific innovation, but also by development speed. As competition from Chinese biotech grows, AI could help accelerate drug development and improve efficiency.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-
Bidding War Heats Up: Pfizer vs. Novo Nordisk in the Race to Acquire Metsera
The intense bidding war between Pfizer and Novo Nordisk over Metsera underscores just how fiercely the global obesity-drug market is being contested.
-
Eli Lilly’s Major Netherlands Plant Investment: Scaling Supply for Oral Obesity Therapy
On November 4, 2025, Eli Lilly and Company announced a multi-billion-dollar investment in a new manufacturing facility in the Netherlands to support global rollout of its oral obesity drug orforglipron and fortify its trans-Atlantic production network.
-
FDA and HHS Announce Biosimilar Reform — No More Comparative Trials, Full Interchangeability Ahead
The U.S. FDA and HHS have announced a landmark reform to eliminate comparative efficacy trials for biosimilars, aiming to reduce development costs and expand patient access to affordable biologic medicines.
-
Key Pharma & Biotech Trends That Defined 2025
A personal look back at the key pharma and biotech trends that shaped 2025 — from AI-driven drug discovery to mRNA innovation and sustainable healthcare.